QBiotics announces first patient dosed in its Phase I/II clinical trial of tigilanol tiglate for head and neck cancer

3 December 2019 First patient successfully dosed in QBiotics' Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC). Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for solid tumours. The Phase I/II clinical trial is a dose escalation study in HNSCC patients designed to determine optimal dosage, safety and tumour response. The QBC46-H03 trial is being run in Australia and India. Read the full news release

The release as fetched from its publisher. qbiotics.com ↗